Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:3608 |
| Name | appendix adenocarcinoma |
| Definition | An appendix carcinoma that derives_from epithelial cells of glandular origin. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer appendix cancer appendix carcinoma appendix adenocarcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| BRAF V600E | Encorafenib + Panitumumab | appendix adenocarcinoma | sensitive | detail... |
| BRAF V600E | Cetuximab + Encorafenib | appendix adenocarcinoma | sensitive | detail... |
| RET fusion | Selpercatinib | appendix adenocarcinoma | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01061515 | Phase I | Capecitabine Bevacizumab Oxaliplatin | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | Active, not recruiting | USA | 0 |
| NCT02834013 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
| NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
| NCT03108131 | Phase II | Atezolizumab + Cobimetinib | Cobimetinib and Atezolizumab in Advanced Rare Tumors | Completed | USA | 0 |
| NCT03693846 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Terminated | USA | 0 |
| NCT04158349 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer (IPOX-FOLFIRI) | Terminated | USA | 0 |
| NCT04665921 | Phase I | SGN-STNV | A Study of SGN-STNV in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
| NCT05121038 | Phase Ib/II | CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX) | Active, not recruiting | USA | 0 |
| NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |